1. In Vivo
  2. >>Leadership

New AdvaMed Chair Lobo: Devices Has A Good Story To Tell

Nadim Yared Will Be A Hard Act To Follow For New AdvaMed Chair Kevin Lobo

 
• By Ashley Yeo

A whirlwind two-year stint as chair of the US medtech industry association, AdvaMed, came to end this month for CVRx’e energetic CEO Nadim Yared. Incoming chair, Stryker’s Kevin Lobo, comes from an altogether much larger concern, but he will continue Yared’s legacy of supporting SMEs, as well as bringing his own agenda to the role.

Stryker CEO Kevin Lobo
Kevin Lobo, CEO of Stryker and new AdvaMed chair • Source: Advamed/Stryker

CVRX CEO Nadim Yared will be a hard act to follow as AdvaMed chair, as his list of accomplishments over the past two years, as well as his ability to maintain the spotlight on the medtech industry in the US and beyond, have shown. In Kevin Lobo, CEO of Stryker Corp., the industry has a leader who will continue to push back the boundaries for SMEs, as well as developing his own agenda points.

Lobo’s two-year tenure was announced on March 27, and he knows that the 2012 medical device excise tax will continue...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.